

*Michael Gladstone is a partner at Atlas Venture, a Cambridge, USA-based biotech venture capital firm focused on venture creation.*

*Michael is a co-founder and board member of Diagonal Therapeutics, Kailera Therapeutics, and Caldera Bio, and he is a board member of Pheon Therapeutics and several stealth NewCos. Michael was previously a board director for Aiolos Bio (acquired by GSK), Day One Biopharmaceuticals (NASDAQ: DAWN), Third Harmonic Bio (NASDAQ: THRD), Versanis Bio (acquired by Lilly), and a board observer for Akero (NASDAQ: AKRO), AvroBio (NASDAQ: AVRO), Delinia (acquired by Celgene), Replimune (NASDAQ: REPL), and Xilio Therapeutics (NASDAQ: XLO).*

*Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin.*

*Michael received an AB in biochemical sciences with highest honors from Harvard College.*